MAOB and Parkinson disease: A pragmatic, randomized, open-label study in which patients with newly diagnosed PD were randomized to levodopa, a dopamine agonist, or a MAO-B inhibitor, found that patients treated with levodopa had better PDQ-39 mobility scores than those treated with a dopamine agonist or MAO-B inhibitor, and patients randomized to a levodopa-sparing approach discontinued those medications due to side effects at a higher rate than those treated with levodopa [36].